Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Anna Greka
University of Nebraska Medical Center, Department: Other Basic Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Goldfinch Biopharma, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The research proposes to define the molecular mechanisms by which TRPC channels lead to proteinuria and FSGS, and identify and validate inhibitors of these channels as novel therapeutics for the treatment of FSGS. Goldfinch Biopharma is a startup biotechnology company that aims to identify, validate, and pursue novel therapeutic targets to treat progressive kidney diseases. The company focuses on developing genetic‐based therapeutic treatments for Focal Segmental Glomerulosclerosis (FSGS) and Polycystic Kidney Disease (PKD). The company does not currently have any drugs on its pipeline. The committee determined that the aims of the research were relevant to the company’s genetic research and pharmacologic intervention efforts. It further determined that since the company was still in the early stages of formation, the research results could affect the company’s business orientation and research direction, and concluded that the financial interest was related to the research as defined by the PHS regulations, and given its nature and magnitude, the financial interest could directly and significantly affect the design, conduct, or reporting of the research. Therefore, the financial interest in connection with the research constitutes a Financial Conflict of Interest under PHS regulations.
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics
Kidney filtration is an important process in retention of vital proteins in the blood and removing waste from the body and damage to this filtration can lead to albuminuria (albumin present in the urine), the single strongest predictor of kidney function decline. It has been shown that the ion channel TRPC5 mediates filtration barrier injury. This work could have substantial contributions to medicine due to the fact that Focal Segmental Glomerulosclerosis is a largely untreated disease.
Filed on August 08, 2017.
Tell us what you know about Anna Greka's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Anna Greka”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Anna Greka | Brigham and Women's Hospital | Conflict of Interest | Goldfinch Biopharma, Inc. | $20,000 - $39,999 |
| Anna Greka | Brigham and Women's Hospital | Conflict of Interest | Goldfinch Biopharma, Inc. | $20,000 - $39,999 |
| Anna Greka | University of Nebraska Medical Center | Conflict of Interest | Goldfinch Biopharma, Inc. | $250,000 - $299,999 |
| Anna Greka | Brigham and Women's Hospital | Conflict of Interest | Goldfinch Biopharma, Inc. | $250,000 - $299,999 |
| Anna Greka | Brigham and Women's Hospital | Conflict of Interest | Goldfinch Biopharma, Inc. | Value cannot be readily determined |
| Anna Greka | Brigham and Women's Hospital | Conflict of Interest | Goldfinch Biopharma, Inc. | $250,000 - $299,999 |
| Anna Greka | Brigham and Women's Hospital | Conflict of Interest | Goldfinch Biopharma, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.